Comunicati Stampa

MONTREAL, QUEBEC--(Marketwire - 3 dicembre 2009) - Bombardier Inc . (TSX: BBD . A)(TSX: BBD . B)(Tutte le cifre di questo comunicato stampa sono in dollari USA eccetto dove indicato)- Utili consolidati di 4,6 miliardi di %24;, in linea con l ultimo anno fiscale- EBITDA di 388 milioni di %24;, contro i 435 milioni di %24; dell ultimo anno fiscale- EBIT di 262 milioni di %24;, contro i 296 milioni di %24; dell ultimo anno fiscale- Reddito netto di 168 milioni di %24;, contro i 226 milioni di %24; dell ultimo anno fiscale- Utile per azione di 0,09 %24;, contro i 0,12 %24; dell ultimo anno fiscale- Free cash flow of %24;72 million, compared to a usage of %24;226 million last fiscal year- Strong cash position at %24;3 billion- Backlog of %24;47 . 4 billion- Landmark order to supply 80 ZEFIRO 380 very high speed trains in China- Subsequent to quarter end, order for 22 CRJ700 regional jetsBombardier today reported its financial results for the third quarter ended October 31, 2009 . Revenues reached the same level as last year at %24;4 . 6 billion . Earnings before financing income, financing expense and income taxes (EBIT) totalled %24;262 million, compared to %24;296 million last fiscal year, while the EBIT margin reached 5 . 7% compared to last year s 6 . 5% . Net income amounted to %24;168 million, compared to %24;226 million for the same period last fiscal year . Free cash flow (cash flows from operating activities less net additions to property, plant and equipment and intangible assets) stood at %24;72 million for the third quarter, compared to a free cash flow usage of %24;226 million for the same period last fiscal year . The cash position remains strong at %24;3 billion, compared to %24;3 . 5 billion as at January 31, 2009 . The overall backlog stood at %24;47 . 4 billion, compared to %24;48 . 2 billion as at January 31, 2009 . "Despite early signs of a recovery, the economic environment remains difficult and continued to impact our activities and financial results, especially in Bombardier Aerospace", said Pierre Beaudoin, President and Chief Executive Officer, Bombardier Inc . "However, Bombardier Transportation continues to improve its revenues, profitability and order intake . ""Our backlog and balance sheet are strong . Both groups continue to look for ways to reduce overall costs in their operations and improve their working capital, while maintaining investments in new product development . We will be ready when the economy recovers", concluded Mr . Beaudoin . Bombardier AerospaceBombardier Aerospace s revenues amounted to %24;2 . 1 billion, compared to %24;2 . 3 billion last fiscal year . EBIT totalled %24;103 million, or 5% of revenues, compared to %24;176 million, or 7 . 7%, for the same period last fiscal year . Free cash flow for the third quarter ended October 31, 2009 reached %24;61 million compared to %24;9 million for the same period last fiscal year . The backlog stood at %24;18 . 1 billion as at October 31, 2009, compared to %24;23 . 5 billion as at January 31, 2009 . Although the business aircraft market is still experiencing difficulties, there are some signs of stabilization . Bombardier Business Aircraft net orders for the third quarter ended October 31, 2009 returned to a positive position for the first time since the third quarter of last fiscal year . Bombardier Commercial Aircraft experienced a low level of order intake during the three-month period ended October 31, 2009 reflecting the significantly reduced demand for commercial aircraft, consistent with the current worldwide economic environment . However, subsequent to quarter end, AMR Eagle Holding Corporation, the parent company of American Eagle Airlines, Inc . , signed a firm order agreement for 22 CRJ700 regional jets, for a value of approximately %24;779 million . The transaction represents the conversion of 22 of the options held by the airline . Despite this recent order, projected CRJ aircraft sales remain insufficient to maintain the current production plan . Bombardier Aerospace thus announced on November 26 a further reduction of the CRJ aircraft production rates . Total deliveries of 61 aircraft compare to 80 for the same period last fiscal year with the Commercial Aircraft segment contributing 27 of these deliveries compared to 22 last fiscal year . Bombardier Aerospace continues to invest in products, such as the CRJ1000 NextGen regional jet, the Global Vision flight deck, the Learjet 85 and the CSeries aircraft . Highlights of the CSeries program include the groundbreaking of the new testing facility in Mirabel, Canada, and the construction of a new state-of-the-art aircraft wing manufacturing and assembly facility in Belfast, Northern Ireland . Bombardier TransportationBombardier Transportation revenues rose to %24;2 . 5 billion, a %24;254-million increase over the same period last fiscal year . EBIT reached %24;159 million, up from %24;120 million a year ago, while EBIT margin increased to 6 . 3% versus 5 . 3% . Free cash flow reached %24;32 million, compared to a usage of %24;243 million last fiscal year . The order backlog stood at %24;29 . 3 billion as at October 31, 2009, compared to %24;24 . 7 billion as at January 31, 2009, mainly due to a positive currency impact . Economic uncertainty continues to affect the rail industry with low funding availability for the private sector and an ongoing decline in freight traffic . As a result, Bombardier Transportation s freight locomotives and services segments are seeing a lower level of activity . On a positive note, Bombardier Transportation reported new orders worth %24;3 . 6 billion, compared to %24;2 . 8 billion last fiscal year, leading to a book-to-bill ratio of 1 . 4 . In September 2009, Bombardier Sifang Transportation won a %24;4 billion landmark contract to supply 80 ZEFIRO 380 very high speed trains capable of speeds of up to 380 km/h for the Chinese Ministry of Railways . Bombardier s share of the contract is worth %24;2 billion . The group also signed a contract for 99 FLEXITY trams, valued at %24;431 million, for Berlin s transport operator BVG (Berliner Verkehrsbetriebe) . Subsequent to the quarter, Bombardier Transportation received an order for 100 E464 locomotives from Trenitalia, Italian Railways, amounting to approximately %24;383 million . Financial highlights(Unaudited, in millions of U . S . dollars, except per share amounts, whichare shown in dollars)

										Three-month	periods
										ended	October	31
						2009						2008
											Restated(1)
		BA		BT		Total		BA		BT		Total
Revenues	$	2,064	$	2,533	$	4,597	$	2,292	$	2,279	$	4,571
EBITDA	$	197	$	191	$	388	$	288	$	147	$	435
Amortization		94		32		126		112		27		139
EBIT	$	103	$	159		262	$	176	$	120		296
Financing income						-29						-80
Financing expense						70						105
EBT						221						271
Income taxes						53						45
Net income					$	168					$	226
Attributable to:
Shareholders of Bombardier Inc .					$	167					$	222
Non-controlling interests					$	1					$	4
Basic & diluted EPS (in dollars)					$	0 . 09					$	0 . 12
Segmented free cash flow	$	61	$	32	$	93	$	9	$	-243	$	-234
Income taxes and net financing expense						-21						8
Free cash flow					$	72					$	-226

										Nine-month	periods
										ended	October	31
						2009						2008
											Restated(1)
		BA		BT		Total		BA		BT		Total
Revenues	$	6,682	$	7,332	$	14,014	$	7,188	$	7,104	$	14,292
EBITDA	$	648	$	531	$	1,179	$	947	$	460	$	1,407
Amortization		281		88		369		322		94		416
EBIT	$	367	$	443		810	$	625	$	366		991
Financing income						(87)						(223)
Financing expense						210						305
EBT						687						909
Income taxes						159						195
Net income					$	528					$	714
Attributable to:
Shareholders of Bombardier Inc .					$	521					$	699
Non-controlling interests					$	7					$	15
Basic & diluted EPS (in dollars)					$	0 . 29					$	0 . 39
Segmented free cash flow	$	(479)	$	(79)	$	(558)	$	399	$	120	$	519
Income taxes and net financing expense						(169)						(86)
Free cash flow					$	(727)					$	433

(1) Restated following a change in accounting policy related to a newaccounting principle on fair value measurements and following our earlyadoption of section 1602 "Non-controlling interests" . BA: Bombardier Aerospace; BT: Bombardier TransportationFINANCIAL RESULTS FOR THE THIRD QUARTER ENDED OCTOBER 31, 2009ANALYSIS OF RESULTSConsolidated resultsConsolidated revenues totalled %24;4 . 6 billion for the third quarters ended October 31, 2009 and 2008 . For the nine-month period ended October 31, 2009, consolidated revenues reached %24;14 billion, compared to %24;14 . 3 billion for the same period last year . For the third quarter ended October 31, 2009, EBIT amounted to %24;262 million, or 5 . 7% of revenues, compared to %24;296 million, or 6 . 5%, for the same period the previous year . For the nine-month period ended October 31, 2009, EBIT amounted to %24;810 million, or 5 . 8% of revenues, compared to %24;991 million, or 6 . 9%, for the same period last fiscal year . Net financing expense came to %24;41 million for the three-month period ended October 31, 2009, compared to %24;25 million for the corresponding period last year . For the nine-month period ended October 31, 2009, net financing expense totalled %24;123 million, compared to %24;82 million for the same period last year . The %24;16-million and %24;41-million increases for the three- and nine-month periods are mainly due to lower interest income, consistent with lower variable interest rates, and a lower average level of cash on hand and a lower level of invested collateral required under the new BT and BA letter of credit facilities; partially offset by lower interest expense on long-term debt, after the effect of hedges, consistent with lower variable interest rates and positive variations in fair value of financial instruments . The effective income tax rate was 24% and 23 . 1% respectively for the three- and nine-month periods ended October 31, 2009, compared to the statutory income tax rate of 31 . 3% . The lower effective tax rates are mainly due to the positive impact of the recognition of tax benefits related to operating losses and temporary differences . As a result, net income amounted to %24;168 million, or %24;0 . 09 per share, for the third quarter of fiscal year 2010, compared to %24;226 million, or %24;0 . 12 per share, for the same period the previous year . For the nine-month period ended October 31, 2009, net income was %24;528 million, or %24;0 . 29 per share, compared to %24;714 million, or %24;0 . 39 per share, for the same period the previous year . For the three-month period ended October 31, 2009, free cash flow totalled %24;72 million, compared to a free cash flow usage of %24;226 million for the corresponding period the previous year . For the nine-month period ended October 31, 2009, free cash flow usage totalled %24;727 million, compared to free cash flow of %24;433 million for the corresponding period the previous year . As at October 31, 2009, Bombardier s order backlog stood at %24;47 . 4 billion, compared to %24;48 . 2 billion as at January 31, 2009 . Bombardier Aerospace- Revenues of %24;2 . 1 billion- EBITDA of %24;197 million, or 9 . 5% of revenues- EBIT of %24;103 million, or 5% of revenues- Free cash flow of %24;61 million- Net orders of seven aircraft- Order backlog of %24;18 . 1 billionBombardier Aerospace s revenues amounted to %24;2 . 1 billion for the three-month period ended October 31, 2009, compared to %24;2 . 3 billion for the same period the previous year . The decrease is mainly due to a decrease in manufacturing revenues reflecting lower deliveries and selling prices for business aircraft, partially offset by a higher percentage of wide-body aircraft deliveries; partially offset by higher revenues for commercial aircraft mainly due to higher deliveries . For the third quarter ended October 31, 2009, EBIT totalled %24;103 million, or 5% of revenues, compared to %24;176 million, or 7 . 7% of revenues, for the same period the previous year . The 2 . 7 percentage-point decrease is mainly due to lower selling prices for business aircraft, higher cost of sales per unit, mainly due to price escalations of materials, the mix between business and commercial aircraft deliveries, lower margins for services activities, a provision for the write-down of inventories mainly due to lower market values for pre-owned aircraft, and the net negative impact in other expense (income) from the revaluation at the balance sheet date of certain balance sheet accounts in foreign currencies; partially offset by liquidated damages from customers, mainly as a result of business aircraft order cancellations, a net positive variance on certain financial instruments carried at fair value, lower selling, general and administrative expenses, mainly due to lower business aircraft deliveries, and lower amortization expense due to the aerospace program tooling on some aircraft models being fully amortized . Free cash flow amounted to %24;61 million for the third quarter ended October 31, 2009, compared to %24;9 million for the same period last fiscal year . The free cash flow increase is mainly due to a positive period-over-period variation in net change in non-cash balances related to operations; partially offset by lower profitability, and higher net additions to property, plant and equipment and intangible assets . For the quarter ended October 31, 2009, Bombardier Aerospace delivered 61 aircraft, compared to 80 for the same period the previous year . The 61 deliveries consisted of 33 business, 27 commercial,

Performance03/12/2009 8:00 (MEZ)

SIX Svizzera
Corso di borsa	CHF 74,35
Valore intrinseco (NAV)	CHF 93,80
Premio/(-sconto)	-20,74 %
TecDax Germania
Corso di borsa	EUR 50,00
Valore intrinseco (NAV)	EUR 62,25
Premio/(-sconto)	-19,68 %
All Star Italia
Corso di borsa	EUR 50,00
Valore intrinseco (NAV)	EUR 62,25
Premio/(-sconto)	-19,68 %

Andamento del titolo (SIX), dividendo rettificato
	Share price	Net Asset Value (NAV)
Andamento della quotazione di borsa per l esercizio in corso (dal 1° gennaio 2008)	+11,4 %	+3,9 %
Performance della quotazione di borsa dalla fondazione (nov . 1993)	+264,9 %	+350,5 %
Performance annualizzata della quotazione di borsa dalla fondazione	+8,4 %	+9,8 %
Outperformance (NAV) rispetto al Nasdaq Biotechnology Index dalla fondazione		+267,1 %
Dividendo 2008		CHF 1 . 80

Copyright Hugin Questo comunicato é distribuito da Hugin . L emittente è l unico responsabile per il contenuto del comunicato . [CN#161034]

Informazioni per la stampa: Bombardier annuncia una teleconferenzaRisultati finanziari del terzo trimestre conclusosi il 31 ottobre 2009MONTREAL, QUEBEC-(Marketwire - 2 dicembre 2009) - (TSX: BBD . A)(TSX: BBD . B) - I risultati finanziari di Bombardier Inc . del terzo trimestre conclusosi il 31 ottobre 2009 saranno resi noti giovedì 3 dicembre 2009 . Pierre Beaudoin, Presidente e Direttore operativo di Bombardier Inc . , Guy C . Hachey, Presidente e Direttore operativo di Bombardier Aerospace, Andre Navarri, Presidente e Direttore operativo di Bombardier Transportation e Pierre Alary, Responsabile esecutivo e Direttore finanziario di Bombardier Inc . condurranno una teleconferenza per gli investitori e gli analisti finanziari per analizzare i risultati finanziari del terzo trimestre . DATE: Thursday, December 3, 2009TIME: 10:00 a . m . , Montreal timeA question period intended for the media will take place at the end of this same conference call . To participate, media representatives need simply identify themselves when they register for the call . This conference call will be broadcast live on the Internet at the following address: www . bombardier . comMedia representatives wishing to listen in on the call will be able to do so by dialing one of the following conference call numbers:Integral version: 514-394-9321 or(without translation) 1-866-540-8119 (toll-free in North America)+800-2787-2790 (overseas calls)In English: 514-394-9319 or1-866-240-8935 (toll-free in North America)+800-2492-4460 (overseas calls)In French: 514-394-9317 or1-888-791-1369 (toll-free in North America)+800-4994-8960 (overseas calls)Contacts:Bombardier Inc . Isabelle RondeauDirector, Communications514-861-9481www . bombardier . comBombardier Inc . Shirley ChenierSenior Director, Investor514-861-9481Copyright Hugin Questo comunicato é distribuito da Hugin . L emittente è l unico responsabile per il contenuto del comunicato . [CN#161042]

Comunicato stampaPer pubblicazione immediata - 2 dicembre 2009Seneffe - Belgio, 2 dicembre 2009, IBt Bebig (Reuters: IBTH . BR - Bloomberg: IBTB BB) ha reso noto oggi di aver firmato un accordo di alleanza strategica con Core Oncology, Inc . , con sede a Santa Barbara, California . Lo scopo di questo accordo è inizialmente quello di coprire il mercato incrociato dei prodotti delle due aziende e di definire dei programmi reciproci di R&S . Nell ambito di questo accordo, IBt Bebig ha fatto un investimento di due milioni di USD in Core Oncology sotto forma di prestito subordinato con scadenza prima della fine del 2010 . Both groups are investigating the possibilities to collaborate further together . IBt Bebig is today market leader in Europe for permanent brachytherapy implants used for the treatment of prostate cancer . The group also manufactures and sells, on a worldwide basis, temporary brachytherapy solutions for the treatment of other early stage cancers -through HDR (High-Dose Rate) Co-60 afterloaders equipments or with Ru-106 Ophthalmic plaques . Core Oncology sells both I-125 and Pd-103 seeds throughout North America where it has aggressively developed a nationwide sales network allowing it to rank today as one of the top 4 in terms of market share . It also distributes a marker primarily used in the area of MRI (Magnetic Resonance Imaging) . The company manufactures its own I-125 implants at its Oklahoma facility . "We are very excited about this transatlantic collaboration and the perspectives it opens up in terms of innovation and new products development," indicated Travis Gay, Chief Executive Officer of Core Oncology . "The North American market remains by far the largest in the World for prostate cancer treatment by permanent brachytherapy implants . We believe that this strategic alliance represents a unique opportunity to get back to a market which is around three to four times the size of the European market," commented François Blondel, Chief Executive Officer of IBt Bebig . About Core OncologyCore Oncology was founded September 15, 2006 by the existing management of the brachytherapy business owned by Coloplast, formerly Mentor, for the sole purpose of enhancing the levels of service and continuing our pursuit of innovation within the field of Radiation Oncology . Our philosophy is to make our Customers and their trusted patients the focus of our business . Meeting their needs is our primary goal . This is how we derived our name Core Oncology, as our Customers and Patients are our center, our focus, our core . On June 8, 2007, Core Oncology completed its acquisition of Mills Biopharmaceuticals LLC, the recently acquired brachytherapy division of Coloplast . Prior to this, the brachytherapy division was owned by Mentor Corporation . Initially formed in 1997, Mentor s brachytherapy division entered the radiation oncology market as the first company to offer both iodine and palladium brachytherapy sources . Since then the division has developed and successfully launched numerous innovative delivery technologies and services, including the Isoloader® workstation, prescription loaded needle services and proprietary cartridge systems for the Mick® applicator . This division has maintained a track record of strong year-on-year growth in a highly competitive market space . The management team that has facilitated the growth and development of the brachytherapy division is the same team that now manages Core Oncology . This team has remained intact from the beginning of the business . We pride ourselves on the culture that we have established and the employee retention that has resulted . About IBt Bebig . . . Contributing to saving lives!The IBt Bebig group is a European based group, active in the Medical Device segment of the Health Care sector . The core business of the IBt Bebig group is the cancer treatment by radiation technology . Its specificity is the treatment of cancer by brachytherapy, a technique which consists of placing a sealed implant containing a minuscule quantity of a radioactive isotope in the body, on either a temporary or on a permanent basis . Depending on the application, the implant can take the shape of a plaque, a seed or a catheter . The precise positioning of the implant allows the cancer cells to be destroyed while sparing the healthy tissues and increasing the patient s quality of life . Today, the alternative brachytherapy procedures cover the non-invasive treatment of cancers of the prostate, neck, head and eye, as well as certain gynecological cancers . The IBt Bebig group employs over 150 people and has entities in Germany, France, United Kingdom, Spain, Italy and India . Its Head Office is located in Seneffe, Belgium and the company has been listed on the Euronext stock exchange since April 1997 (Reuters : IBTH . BR - Bloomberg : IBTB BB) . ContactPaul-Emmanuel GoethalsHead of Investor Relations & CommunicationTel: +32 . 64 . 520 . 808E-mail: ir@ibt-bebig . euInternet: www . ibt-bebig . euCopyright Hugin Questo comunicato é distribuito da Hugin . L emittente è l unico responsabile per il contenuto del comunicato . [CN#161045]

Performance02/12/2009 8:00 (MEZ)

SIX Svizzera
Corso di borsa	CHF 74,75
Valore intrinseco (NAV)	CHF 92,85
Premio/(-sconto)	-19,49 %
TecDax Germania
Corso di borsa	EUR 49,40
Valore intrinseco (NAV)	EUR 61,60
Premio/(-sconto)	-19,81 %
All Star Italia
Corso di borsa	EUR 49,42
Valore intrinseco (NAV)	EUR 61,60
Premio/(-sconto)	-19,77 %

Andamento del titolo (SIX), dividendo rettificato
	Share price	Net Asset Value (NAV)
Andamento della quotazione di borsa per l esercizio in corso (dal 1° gennaio 2008)	+12,0 %	+2,9 %
Performance della quotazione di borsa dalla fondazione (nov . 1993)	+266,8 %	+345,9 %
Performance annualizzata della quotazione di borsa dalla fondazione	+8,4 %	+9,8 %
Outperformance (NAV) rispetto al Nasdaq Biotechnology Index dalla fondazione		+266,3 %
Dividendo 2008		CHF 1 . 80

Copyright Hugin Questo comunicato é distribuito da Hugin . L emittente è l unico responsabile per il contenuto del comunicato . [CN#161000]

MONTREAL, QUEBEC--(Marketwire - 1 dicembre, 2009) - (TSX: BBD . A)(TSX: BBD . B)- Ruolo accresciuto della responsabilità sociale d impresa nella strategia aziendale- Raggiunta la riduzione del 10% delle emissioni di gas ad effetto serra tra l esercizio fiscale 2004 e 2009 e obiettivo di ridurre le emissioni di un ulteriore 10% entro il 2015 . Oggi Bombardier Inc ha pubblicato il suo secondo report di responsabilità sociale di impresa relativo alla totalità delle sue attività, dal titolo "La responsabilità come spinta verso il futuro" . Il report sintetizza l impegno da parte della società ad agire in modo responsabile in qualità di società pubblica, datore di lavoro, vicino e partner . Descrive anche dettagliatamente in che modo la responsabilità sociale di impresa costituisca una delle principali priorità della strategia di impresa di Bombardier, "La via verso il futuro""A sharper focus on corporate social responsibility augurs well for all of our stakeholders . It underscores our commitment to leverage our industry-leading innovation, talents, products and resources to increase our positive contribution to the communities where we are present around the world," said Pierre Beaudoin, President and Chief Executive Officer, Bombardier Inc . The report highlights recent achievements and details how Bombardier is laying the foundation to continuously improve its corporate social responsibility performance in the years to come . The report is organized into six sections, reflecting both stakeholder feedback and the areas where Bombardier has the greatest responsibilities: governance, employees, products, operations, suppliers and responsible citizenship . To improve access and minimize its environmental footprint, Bombardier s complete 2009 Corporate Social Responsibility Report is available exclusively online at /www . bombardier . com/en/corporate/corporate-responsibility . Highlights include:- Listing on the Dow Jones Sustainability World and Dow Jones Sustainability North America Indexes for the third consecutive year- Ongoing and active promotion of the UN Global Compact s principles of social responsibility and embedding of these principles in Bombardier s Code of Ethics and Business Conduct- Enhanced approach to health and safety to reach the objective of zero accidents and occupational illnesses- Expansion of the ECO4 portfolio of breakthrough energy-saving rail solutions, which can reduce overall energy consumption by up to 50%- Continued development of the environmentally focused CSeries aircraft program, which will contribute to the commercial aviation industry s commitment to achieve carbon-neutral growth by 2020- Recognition as one of the 10 Canadian Climate Disclosure Leaders in the Carbon Disclosure Project 2009 - Canada 200 Report- Obtained commitment to respect Bombardier s Supplier Code of Conduct from 83 suppliers in Aerospace and over 120 in Transportation to dateAbout BombardierA world-leading manufacturer of innovative transportation solutions, from commercial aircraft and business jets to rail transportation equipment, systems and services, Bombardier Inc . is a global corporation headquartered in Canada . Its revenues for the fiscal year ended Jan . 31, 2009, were %24;19 . 7 billion US, and its shares are traded on the Toronto Stock Exchange (BBD) . Bombardier is listed as an index component to the Dow Jones Sustainability World and North America indexes . News and information are available at www . bombardier . com . CSeries and ECO4 are trademarks of Bombardier Inc . or its subsidiaries . Contacts:Bombardier Inc . Isabelle RondeauDirector, Communications514-861-9481Bombardier Inc . Shirley ChenierSenior Director, Investor Relations514-861-9481www . bombardier . comCopyright Hugin Questo comunicato é distribuito da Hugin . L emittente è l unico responsabile per il contenuto del comunicato . [CN#161011]

Performance01/12/2009 8:00 (MEZ)

SIX Svizzera
Corso di borsa	CHF 72,25
Valore intrinseco (NAV)	CHF 91,70
Premio/(-sconto)	-21,21 %
TecDax Germania
Corso di borsa	EUR 48,69
Valore intrinseco (NAV)	EUR 60,80
Premio/(-sconto)	-19,92 %
All Star Italia
Corso di borsa	EUR 49,00
Valore intrinseco (NAV)	EUR 60,80
Premio/(-sconto)	-19,41 %

Andamento del titolo (SIX), dividendo rettificato
	Share price	Net Asset Value (NAV)
Andamento della quotazione di borsa per l esercizio in corso (dal 1° gennaio 2008)	8,3 %	1,6 %
Performance della quotazione di borsa dalla fondazione (nov . 1993)	254,6 %	340,4 %
Performance annualizzata della quotazione di borsa dalla fondazione	8,2 %	9,7 %
Outperformance (NAV) rispetto al Nasdaq Biotechnology Index dalla fondazione		260,7 %
Dividendo 2008		CHF 1 . 80

Copyright Hugin Questo comunicato é distribuito da Hugin . L emittente è l unico responsabile per il contenuto del comunicato . [CN#160957]

Comunicato stampaEmbargo fino alle 17:40 (ora del Belgio) - 30 novembre 2009Seneffe - Belgio, 30 novembre 2009, IBt Bebig (Reuters: IBTH . BR - Bloomberg: IBTB BB) ha reso noto oggi di aver raggiunto una partecipazione record durante il suo meeting International User Group che si è tenuto dal 27 al 29 novembre nel prestigioso Hotel Metropole a Bruxelles, Belgio . IBt Bebig ha riunito più di 150 persone specializzate nel campo della brachiterapia temporanea o permanente, tra cui medici e professori provenienti soprattutto dall Europa ma anche dall Asia e dal Sudamerica . Nel corso del meeting, un comitato scientifico multidisciplinare composto dai più eminenti radiologi oncologici, urologi e medici fisici, ha diretto le sessioni della conferenza . A panel of well recognized experts has discussed about usage of temporary brachytherapy (High-Dose rate) to treat gynecological, head & neck tumors, as well as ocular melanoma treated by local implants . Some of the other subjects were covering the trends in prostate cancer treatment, such as the latest developments in permanent prostate brachytherapy . During the meeting, IBt Bebig provided a platform to the participants to share their scientific, clinical and practical experiences . "We are very pleased to have gathered together so many scientists in Brussels for our User Group meeting to discuss the trends and the future of brachytherapy . The success of the meeting clearly confirms the European leadership of IBt Bebig in its field . And I am looking forward to repeat this experience in the future," commented François Blondel, Chief Executive Officer of IBt Bebig . "The success of this User Group meeting, with a large audience of 150 specialists, unequivocally proves the regularly increasing interest to treat localized prostate cancers with permanent or temporary radioactive implants . During this meeting, we have been able to present, both from the literature data and also from our own experience of more than 2200 treated cases, excellent long-term results for the treatment of prostate cancer with permanent implants - both in terms of (high) tumor control and in terms of (low) long-term toxicity," said Professor Jean-Marc Cosset, Radiation Oncology, Institut Curie, Paris . About IBt Bebig . . . Contributing to saving lives!The IBt Bebig group is a European based group, active in the Medical Device segment of the Health Care sector . The core business of the IBt Bebig group is the cancer treatment by radiation technology . Its specificity is the treatment of cancer by brachytherapy, a technique which consists of placing a sealed implant containing a minuscule quantity of a radioactive isotope in the body, on either a temporary or on a permanent basis . Depending on the application, the implant can take the shape of a plaque, a seed or a catheter . The precise positioning of the implant allows the cancer cells to be destroyed while sparing the healthy tissues and increasing the patient s quality of life . Today, the alternative brachytherapy procedures cover the non-invasive treatment of cancers of the prostate, neck, head and eye, as well as certain gynecological cancers . The IBt Bebig group employs over 150 people and has entities in Germany, France, United Kingdom, Spain, Italy and India . Its Head Office is located in Seneffe, Belgium and the company has been listed on the Euronext stock exchange since April 1997 (Reuters : IBTH . BR - Bloomberg : IBTB BB) . ContactPaul-Emmanuel GoethalsHead of Investor Relations & CommunicationTel: +32 . 64 . 520 . 808E-mail: ir@ibt-bebig . euInternet: www . ibt-bebig . euCopyright Hugin Questo comunicato é distribuito da Hugin . L emittente è l unico responsabile per il contenuto del comunicato . [CN#160967]